Clinical Trial Update: A Long-term Follow-up Study in Participants Who Received CTX001 [Phase 3]

View source ↗

Summary

A long-term follow-up update on participants who received CTX001 in a Phase 3 study, reporting safety and durability data for beta-thalassemia and sickle cell d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• CTX001

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Beta-Thalassemia, Thalassemia | Phase 3 | Status: ENROLLING_BY_INVITATION